Abbott Receives Positive Opinion for HUMIRA in Ulcerative Colitis from EMA's CHMP
Abbott (NYSE: ABT) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for HUMIRA (adalimumab) in adults with moderate to severely active ulcerative colitis (UC) who have not responded to, cannot tolerate or have medical contraindications to conventional therapies. Based on the CHMP's positive opinion, a final decision from the European Commission is anticipated in the next few weeks. Upon final decision, HUMIRA will be the first and only self-injectable biologic therapy available for moderate to severe UC patients.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.